Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deals

Set Alert for Deals

Genentech Bets On Kineta's Early-Stage, Disease-Modifying Pain Therapy

Genentech partners with the Seattle biotech on a non-opioid approach to chronic pain. Kineta says there's disease-modifying potential.
Deals Neurology Commercial
Advertisement

Deals

Set Alert for Deals

Latest From Deals

Servier's Shire Oncology Buy Gives Base For US Expansion

With the $2.4bn acquisition of Shire's oncology assets, including Oncaspar and Onivyde, the French drug maker has laid down a marker to become a key player in cancer and sees the US in particular as the land of opportunity.

M & A Cancer

Servier Acquires Shire Oncology Business For $2.4bn

French pharma Servier takes step to meet its strategic ambition of becoming a global player in oncology by acquiring Shire's cancer franchise for $2.4bn

M & A Commercial

Finance Watch: VC Investment Soars In Q1, Putting Biopharma On Track For A Record Year

Pharma and biotech companies raised $4.6bn in the first quarter, exceeding the 2017 quarterly average by $1.4bn. But while the money invested soared, the number of companies funded sank. In public financings, MorphoSys commences US IPO and Mylan sells $1.5bn in notes.

Deals Financing

Venture Funding Deals: MedImmune Spinout Viela Lands $250m Series A

China's JW Therapeutics nets $90m for cancer cell therapy, including backing from biotechs Celgene and WuXi. Meanwhile, Foghorn sounds out a $50m A round for its gene trafficking technology applications.

Deals Financing

Orchard To Use Divested GSK Rare Disease Gene Therapies To Grow Globally

Orchard Therapeutics will acquire GSK’s portfolio of approved and investigational rare disease gene therapies, including EU-approved Strimvelis and additional late-stage gene therapies.

Analysis Business Strategies

Genentech BD Director Reviews Recent Technology Deals

Mark Rowan, associate director of business development at Genentech, talks to Scrip at BIO-Europe Spring 2018 about the company's recent technology deals with DiCE Molecules and FinnGen.

Research and Development Strategies StartUps and SMEs
See All
UsernamePublicRestriction

Register